semaglutide hockley More than half of all US adults are eligible for therapy GLP-1 Weight Loss Treatment (Semaglutide)

Local pickup or New Jersey delivery

Snapshot of the 2026 Speaker Faculty Top Takeaways: Unlocked the next generation of GLP-1 combinations and gained competitive intelligence on multi-agonist and combination therapies designed to enhance efficacy, minimize muscle loss, and improve body composition for superior patient outcomes Discovered high-value indication expansion and explored the next frontier of GLP-1 development beyond obesity through exclusive data on clinical programs targeting liver, renal and cardiometabolic disorders alongside neurological diseases and womens health conditions Mastered alternative delivery and patient adherence through dedicated sessions focused on overcoming the challenges of administration through oral programs and less frequent dosing strategies for long-term patient success Benchmarked against industry titans and innovators and heard directly from the companies leading the pipeline, including experts from Eli Lilly , Constructive Bio and Regeneron

The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes

Administered as a once-weekly injection under medical supervision, they offer a non-surgical option for patients looking for additional support in their weight management journey

NAION is sometimes described as an eye stroke because reduced blood flow damages the optic nerve, often causing painless blindness in one eye, loss of peripheral vision, blurred vision, or darkened visual fields that may not recover